Table 1.
Fusion Gene | Year | Expression | Mechanism | Phenotype | References |
---|---|---|---|---|---|
RUNX1-RUNX1T1 | 2006 | Constitutive | Retrovirus | 9a isoform: AML | (37) |
2001 | Constitutive | Germline - Mrp8 promoter (myeloid specific) | AML, T-ALL after ENU treatment | (38) | |
2013 | Inducible | Tet-On | MDS | (39) | |
2021 | Inducible | eR1-CreERT2 | AML, MPD | (40) | |
CBFB-MYH11 | 2006 | Inducible | Mx1-Cre | AML | (41) |
KMT2A-MLLT3 | 1996 | Constitutive | Germline | AML | (42) |
2000 | Inducible | Lmo2-Cre | AML | (43) | |
2013 | Constitutive | Retrovirus | AML (Transduced LSKs > GMP) | (44) | |
2016 | Inducible | Retrovirus | AML | (45) | |
MLL-PTD | 2012 | Constitutive | Germline | AML (if FLT3-ITD mutated) | (46) |
KMT2A-MLLT1 | 2013 | Inducible | CreER | ALL | (47) |
2014 | Inducible | Tet-On | ALL | (48) | |
NUP98-NSD1 | 2007 | Constitutive | Retrovirus | AML | (49) |
2014 | Constitutive | Retrovirus | AML (if FLT3-ITD mutated) | (50) | |
2020 | Constitutive | Retrovirus | AML | (51) | |
Other NUP98 fusions | 2020 | Inducible | Tet-On Retrovirus | AML | (52) |
CBFA2T3-GLIS2 | 2019 | Inducible | Tet-On | AML | (53) |
PML-RARA | 1997 | Constitutive | Germline – Ctsg promoter (myeloid specific) | AML – long latency | (54) |
1999 | Constitutive | Retrovirus | Differentiation blockade, enhanced self-renewal | (55) | |
2003 | Constitutive | Germline – Mrp8 promoter (myeloid specific) | AML | (56) |
AML, acute myeloid leukemia; ENU, N-ethyl-N-nitrosurea; GMP, granulocyte-macrophage progenitor; ITD, internal tandem duplication; LSK, Lin-Sca1+Kit+; MDS, myelodysplastic syndrome; MPD, myeloproliferative disease; PTD, partial tandem duplication; T-ALL, T-acute lymphoblastic leukemia.